Literature DB >> 7872758

Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition.

K Hoshino1, A Kitamura, I Morrissey, K Sato, J Kato, H Ikeda.   

Abstract

In order to examine the inhibitory activities of quinolones against topoisomerase IV, both subunits of this enzyme, ParC and ParE, were purified from Escherichia coli. The specific activity of topoisomerase IV decatenation was found to be more than five times greater than that of topoisomerase IV relaxation. Thus, the decatenation activity of topoisomerase IV seems the most relevant activity for use in studies of drug inhibition of this enzyme. Although topoisomerase IV was less sensitive to quinolones than DNA gyrase, the 50% inhibitory concentrations for decatenation were significantly lower than those for type I topoisomerases. Moreover, there was a positive correlation between the inhibitory activity against topoisomerase IV decatenation and that for DNA gyrase supercoiling. These results imply that topoisomerase IV could be a target for the quinolones in intact bacteria and that quinolones could inhibit not only supercoiling of DNA gyrase but also decatenation of topoisomerase IV when high concentrations of drug exist in bacterial cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7872758      PMCID: PMC188252          DOI: 10.1128/AAC.38.11.2623

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

1.  Purification and characterization of DNA topoisomerase IV in Escherichia coli.

Authors:  J Kato; H Suzuki; H Ikeda
Journal:  J Biol Chem       Date:  1992-12-25       Impact factor: 5.157

2.  The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication.

Authors:  D E Adams; E M Shekhtman; E L Zechiedrich; M B Schmid; N R Cozzarelli
Journal:  Cell       Date:  1992-10-16       Impact factor: 41.582

3.  Decatenating activity of Escherichia coli DNA gyrase and topoisomerases I and III during oriC and pBR322 DNA replication in vitro.

Authors:  H Hiasa; R J DiGate; K J Marians
Journal:  J Biol Chem       Date:  1994-01-21       Impact factor: 5.157

4.  Decatenation activity of topoisomerase IV during oriC and pBR322 DNA replication in vitro.

Authors:  H Peng; K J Marians
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

5.  Topoisomerase mutations affect the relative abundance of many Escherichia coli proteins.

Authors:  T R Steck; R J Franco; J Y Wang; K Drlica
Journal:  Mol Microbiol       Date:  1993-11       Impact factor: 3.501

6.  Chromosomal supercoiling in Escherichia coli.

Authors:  W G Miller; R W Simons
Journal:  Mol Microbiol       Date:  1993-11       Impact factor: 3.501

7.  Limitations of plasmid complementation test for determination of quinolone resistance due to changes in the gyrase A protein and identification of conditional quinolone resistance locus.

Authors:  C J Soussy; J S Wolfson; E Y Ng; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

8.  Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions.

Authors:  H Peng; K J Marians
Journal:  J Biol Chem       Date:  1993-11-15       Impact factor: 5.157

9.  Antimicrobial activity of DV-7751a, a new fluoroquinolone.

Authors:  M Tanaka; K Hoshino; H Ishida; K Sato; I Hayakawa; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

10.  Synthesis and antibacterial activities of optically active ofloxacin.

Authors:  I Hayakawa; S Atarashi; S Yokohama; M Imamura; K Sakano; M Furukawa
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

View more
  49 in total

1.  Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms.

Authors:  V J Heaton; C E Goldsmith; J E Ambler; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

2.  Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli.

Authors:  S Bagel; V Hüllen; B Wiedemann; P Heisig
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

3.  A Roadblock-and-Kill Mechanism of Action Model for the DNA-Targeting Antibiotic Ciprofloxacin.

Authors:  Nikola Ojkic; Elin Lilja; Susana Direito; Angela Dawson; Rosalind J Allen; Bartlomiej Waclaw
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

Review 4.  DNA gyrase, topoisomerase IV, and the 4-quinolones.

Authors:  K Drlica; X Zhao
Journal:  Microbiol Mol Biol Rev       Date:  1997-09       Impact factor: 11.056

5.  Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins.

Authors:  I Morrissey; J George
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

6.  Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases.

Authors:  T Akasaka; S Kurosaka; Y Uchida; M Tanaka; K Sato; I Hayakawa
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

7.  Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci.

Authors:  I González; M Georgiou; F Alcaide; D Balas; J Liñares; A G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

8.  Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.

Authors:  E Y Ng; M Trucksis; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

9.  Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli.

Authors:  P Heisig
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

10.  Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene.

Authors:  Y Kumagai; J I Kato; K Hoshino; T Akasaka; K Sato; H Ikeda
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.